May 24, 2023 07:01 AM EDTUpdated 07:40 AM
R&D
Cell/Gene Tx

PTC cuts gene ther­a­py pro­grams, dis­clos­es PhI­II fail in Friedre­ich's atax­ia and CFO ex­it

Amber Tong

PTC Ther­a­peu­tics dis­closed a string of dis­ap­point­ing news late Tues­day, re­veal­ing a Phase III flop, a pipeline re­org to cut

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Am­gen’s once-a-month obe­si­ty shot shows 20% weight loss af­ter a year

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

A service from the Financial Times